---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000009"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-03-17T23:59:59+00:00"
generated_at: "2026-06-17T23:37:46.627688+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3

## Summary
- Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.
- TORREY open-label extension topline data expected mid-2023.
- GB5121 Phase 1b/2 enrollment paused due to benefit/risk profile and resource prioritization toward seralutinib.
- Cash of $255.7M at Dec 31, 2022; expected to fund operations into H2 2024.
- Full-year 2022 net loss $229.4M ($2.71/share), vs $234.0M ($3.13/share) in 2021.

## SEC filing metadata
- accession: 0001728117-23-000009
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/goss-20230317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000009
- JSON: https://secwatch.observer/filing/0001728117-23-000009.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000009.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the full year ended December 31, 2022, was $229.4 million, EPS $2.71 per share.
  - Period: the full year ended December 31, 2022
  - Net income: Net loss for the full year ended December 31, 2022, was $229.4 million
  - EPS: $2.71 per share
  - Result: reported results
  source text: Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm
- Earnings Releases
  Gossamer Bio, Inc. reported the three months ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022, was $55.8 million, EPS $0.59 per share.
  - Period: the three months ended December 31, 2022
  - Net income: Net loss for the three months ended December 31, 2022, was $55.8 million
  - EPS: $0.59 per share
  - Result: reported results
  source text: Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000009/0001728117-23-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.